BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• Drug Development

  BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders

  BioXcel Therapeutics, Inc. (Nasdaq: BTAI), today announced the publication of results from its pivotal Phase 3 SERENITY II trial of BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorder in the Journal of the American Medical Association(JAMA).

  February 22, 2022

   · 

  10 min read
• Neurostimulation Devices Market: Newly-Raised Funding to Help Manufacturers to Develop Advanced Devices in Future

  The growth in the global neurostimulation devices market is due to growth in utilization of neurostimulation devices in pain management and upsurge in usage of neurostimulation devices in developing economies.

  February 22, 2022

   · 

  3 min read
• Mice Model Market Size Worth USD 2.00 Billion by 2027 | Industry Trend – Rise in Adoption Of Mice Models For Clinical Research By Contract Research Organizations (Cros)

  The global mice model market is anticipated to reach USD 2.00 Billion by 2027, according to a current analysis by Emergen Research.

  February 22, 2022

   · 

  6 min read
• Deals

  Relevate Health Acquires Axon Communications

  Relevate Health continues its aggressive growth strategy, announcing the acquisition of Boston-based Axon Communications and its proprietary suite of digital healthcare professional (HCP), field team, and patient engagement marketing products.

  February 22, 2022

   · 

  3 min read
• Radiaction Opens First EU Radiation Protection Center of Excellence in Collaboration with Mazowiecki Hospital in Ostrołęka, Poland

  Radiaction Medical Ltd., an innovative medical device company focused on radiation protection in the interventional cardiology and electrophysiology sectors, has entered into a new collaboration with the Interventional Cardiology unit of Mazowiecki Hospital in Ostroleka, Poland.

  February 22, 2022

   · 

  3 min read
• Business

  Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors

  Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”),and AVEO Oncology (NASDAQ: AVEO) (“AVEO”), today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3.

  February 22, 2022

   · 

  7 min read
• Business

  Amyris To Host Fourth Quarter And Full Year 2021 Financial Results Conference Call On March 1

  Amyris, Inc. announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2021, on the morning of Tuesday, March 1, 2022, prior to the opening of the financial markets.

  February 22, 2022

   · 

  1 min read
• Pharm Country

  Janssen Demonstrates Its Commitment to Advancing Transformative Solutions for Multiple Sclerosis at ACTRIMS Forum 2022

  The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 13 company-sponsored data presentations from its multiple sclerosis (MS) research program will be presented at the 2022 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum.

  February 22, 2022

   · 

  17 min read
• Business

  Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

  Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter and full year 2021 financial results on Monday, February 28, 2022 after the close of market.

  February 22, 2022

   · 

  2 min read
• Drug Development

  Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data

  Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease burden among older adults and young children; there is no approved vaccine to prevent RSV.

  February 22, 2022

   · 

  6 min read